Tags

Type your tag names separated by a space and hit enter

Clinical potential of minocycline for neurodegenerative disorders.
Neurobiol Dis 2004; 17(3):359-66ND

Abstract

Minocycline, an antibiotic of the tetracycline family, has been shown to display neurorestorative or neuroprotective properties in various models of neurodegenerative diseases. In particular, it has been shown to delay motor alterations, inflammation and apoptosis in models of Huntington's disease, amyotrophic lateral sclerosis and Parkinson's disease. Despite controversies about its efficacy, the relative safety and tolerability of minocycline have led to the launching of various clinical trials. The present review summarizes the available data supporting the clinical testing of minocycline for these neurodegenerative disorders. In addition, we extend our discussion to the potential applications of minocycline for combining this treatment with cellular and molecular therapy.

Authors+Show Affiliations

Laboratory of Experimental Neurosurgery, ULB-Erasme, 1070 Brussels, Belgium. David.Blum@ulb.ac.beNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

15571972

Citation

Blum, David, et al. "Clinical Potential of Minocycline for Neurodegenerative Disorders." Neurobiology of Disease, vol. 17, no. 3, 2004, pp. 359-66.
Blum D, Chtarto A, Tenenbaum L, et al. Clinical potential of minocycline for neurodegenerative disorders. Neurobiol Dis. 2004;17(3):359-66.
Blum, D., Chtarto, A., Tenenbaum, L., Brotchi, J., & Levivier, M. (2004). Clinical potential of minocycline for neurodegenerative disorders. Neurobiology of Disease, 17(3), pp. 359-66.
Blum D, et al. Clinical Potential of Minocycline for Neurodegenerative Disorders. Neurobiol Dis. 2004;17(3):359-66. PubMed PMID: 15571972.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical potential of minocycline for neurodegenerative disorders. AU - Blum,David, AU - Chtarto,Abdelwahed, AU - Tenenbaum,Liliane, AU - Brotchi,Jacques, AU - Levivier,Marc, PY - 2004/03/26/received PY - 2004/07/01/revised PY - 2004/07/20/accepted PY - 2004/12/2/pubmed PY - 2005/3/8/medline PY - 2004/12/2/entrez SP - 359 EP - 66 JF - Neurobiology of disease JO - Neurobiol. Dis. VL - 17 IS - 3 N2 - Minocycline, an antibiotic of the tetracycline family, has been shown to display neurorestorative or neuroprotective properties in various models of neurodegenerative diseases. In particular, it has been shown to delay motor alterations, inflammation and apoptosis in models of Huntington's disease, amyotrophic lateral sclerosis and Parkinson's disease. Despite controversies about its efficacy, the relative safety and tolerability of minocycline have led to the launching of various clinical trials. The present review summarizes the available data supporting the clinical testing of minocycline for these neurodegenerative disorders. In addition, we extend our discussion to the potential applications of minocycline for combining this treatment with cellular and molecular therapy. SN - 0969-9961 UR - https://www.unboundmedicine.com/medline/citation/15571972/Clinical_potential_of_minocycline_for_neurodegenerative_disorders_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0969-9961(04)00165-2 DB - PRIME DP - Unbound Medicine ER -